Here’s Why Novavax Stock (NVAX) Hit a New 52-Week High on Thursday

FomoAnxiety · 2026-02-27T03:18:13+00:00

Novavax stock surged over 23% to a 52-week high following strong fourth-quarter results, positive partnerships, and a 35% annual gain, reflecting investor optimism in its vaccine platform and commercial strategy.

FomoAnxiety

2026-02-27 03:18:13

Abstract generation in progress

Novavax NVAX +17.42% ▲ stock surged over 23% and hit a new 52-week high on Thursday. Investors reacted to strong fourth-quarter results, growing confidence in its vaccine platform, and several major partnerships that signal a more stable future for the biotech company.

Claim 50% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

Importantly, the stock has gained nearly 35% over the past year, reflecting optimism about Novavax’s cost-cutting efforts and commercial strategy.

What Drove the Stock to a New High?

**Strong Q4 Results: **Earlier today, Novavax reported a stronger-than-expected fourth quarter, swinging back to profitability. The company posted earnings of $0.11 per share, far above expectations for a $0.48 loss and better than the $0.51 loss in the same quarter last year.

Also, the company’s Q4 revenue of $147 million easily surpassed the consensus estimate of $89.86 million and increased 67% year-over-year. The upside was driven by milestone payments from its Sanofi SNY +1.60% ▲ partnership and rising demand for its Matrix‑M adjuvant technology.
**Expanding Partnerships Boost Long-Term Visibility: **A major catalyst behind today’s rally was renewed optimism about Novavax’s partnerships, including a license agreement with Pfizer PFE +0.04% ▲ .

Under the deal, Pfizer will use Novavax’s Matrix‑M adjuvant in up to two vaccine programs, providing a $30 million upfront payment and up to $500 million in potential milestones, plus royalties. These partnerships help validate Novavax’s technology and diversify revenue beyond COVID-19.

Is Novavax Stock a Good Buy?

On TipRanks, NVAX stock has a Hold consensus rating based on three Buy, one Hold, and two Sell ratings. The average Novavax stock price target of $11.50 implies 3.44% downside risk. It’s worth noting that estimates will likely change following today’s earnings report.

Disclaimer & DisclosureReport an Issue

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.